Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20N2O2 |
| Molecular Weight | 308.3743 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(\C=C2/CCCN=C2C3=CC=CN=C3)C(OC)=C1
InChI
InChIKey=RPYWXZCFYPVCNQ-RVDMUPIBSA-N
InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+
| Molecular Formula | C19H20N2O2 |
| Molecular Weight | 308.3743 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:07:00 UTC 2023
by
admin
on
Fri Dec 15 16:07:00 UTC 2023
|
| Record UNII |
8S399XDN2K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NCT00952393
Created by
admin on Fri Dec 15 16:07:00 UTC 2023 , Edited by admin on Fri Dec 15 16:07:00 UTC 2023
|
PRIMARY | Nicotinic Receptors and Schizophrenia | ||
|
8S399XDN2K
Created by
admin on Fri Dec 15 16:07:00 UTC 2023 , Edited by admin on Fri Dec 15 16:07:00 UTC 2023
|
PRIMARY | |||
|
5310985
Created by
admin on Fri Dec 15 16:07:00 UTC 2023 , Edited by admin on Fri Dec 15 16:07:00 UTC 2023
|
PRIMARY | |||
|
GTS-21
Created by
admin on Fri Dec 15 16:07:00 UTC 2023 , Edited by admin on Fri Dec 15 16:07:00 UTC 2023
|
PRIMARY | |||
|
DB05708
Created by
admin on Fri Dec 15 16:07:00 UTC 2023 , Edited by admin on Fri Dec 15 16:07:00 UTC 2023
|
PRIMARY | |||
|
DTXSID701027513
Created by
admin on Fri Dec 15 16:07:00 UTC 2023 , Edited by admin on Fri Dec 15 16:07:00 UTC 2023
|
PRIMARY | |||
|
148372-04-7
Created by
admin on Fri Dec 15 16:07:00 UTC 2023 , Edited by admin on Fri Dec 15 16:07:00 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
GTS-21 was able to improve survival rate of BALB/c mice suffered from endotoxemia when applied in dose 4 mg/kg. As proved on a C57BL6 mouse model, the compound is also suitable for prevention of inflammatory injury induced by mechanical ventilation. In addition to the anti-inflammatory pathway, GTS-21 was assessed in a clinical trial and was proved to improve the cognitive functions of schizophrenic patients.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
